AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround

• Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller.
• Decision to remove Greenleaf and install Tang as CEO represents a “complete validation” of concerns raised for nearly three years, major shareholder MKT Capital said in a statement.
• The company is looking to initiate a clinical study of Aritinercept for an autoimmune disease in the first half of 2026. 

Aurinia Pharmaceuticals (AUPH) drew strong retail interest on Monday after naming Kevin Tang as Chief Executive Officer, fueling investor hopes of a “new positive era” for the company.

AUPH stock was up more than 6% at the time of writing.

Tang, who is also the Chair of the Board, will replace Peter Greenleaf, who has been the company’s CEO for the past 7 years. Tang, an industry veteran, previously served as Chairman of La Jolla Pharmaceutical Company from 2014 through its acquisition by Innoviva in 2022.

In 2013, Tang founded Odonate Therapeutics and served as its Chairman and CEO through 2022. Mr. Tang also co-founded Ardea Biosciences in 2006 and Heron Therapeutics in 2009. From 2009 through its acquisition by Keenova Therapeutics in 2010, Tang served as Director of Penwest Pharmaceuticals Co.

Among other changes, Michael Hearne has been appointed Chief Financial Officer, replacing Joe Miller. Meanwhile, Ryan Cole was appointed as Chief Operating Officer, and Thomas Wei took over as Chief Scientific Officer.

How Did Stocktwits Users React?

Retail sentiment flipped to ‘bullish’ from ‘bearish,’ amid ‘high’ message volumes.

One user speculated on the implications of the management change for the company, akin to the potential for it to go private.

Another user said, “Hopefully this starts the beginning of a new positive era”.

In 2021, Aurinia Pharmaceuticals launched LUPKYNIS, an FDA-approved oral treatment for adults with active Lupus Nephritis. The company also plans to begin a clinical study of Aritinercept for an autoimmune disease in the first half of 2026. Aurinia reported its first full-year profit in December 2024.

MKT’s Statement On Management Changes

MKT Capital, a major long-term shareholder of Aurinia, issued a statement following the appointment of Kevin Tang as CEO.

“Today marks a watershed moment for Aurinia shareholders. Since 2019, we have tirelessly advocated for accountability, disciplined capital allocation, and genuine alignment between management and the true owners of this Company – its shareholders. The Board’s decision to remove CEO Peter Greenleaf and his executive team, and to install Chair Kevin Tang as CEO, represents a complete validation of the concerns we have raised for nearly three years,” said Antoine Khalife, Founder of MKT Capital.

In April 2025, MKT Capital announced its intention to withhold support for Greenleaf at the 2025 Annual General Meeting.

Year-to-date, the stock has fallen 6.5%.

Read also: NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside

For updates and corrections, email newsroom[at]stocktwits[dot]com.